HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Investigation of the risk factors of vomiting during linezolid therapy : a retrospective observational study

Files in This Item:
Eur J Clin Pharmacol s00228-021-03221-x.pdf495.78 kBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Investigation of the risk factors of vomiting during linezolid therapy : a retrospective observational study
Authors: Tsutsumi, Takezo Browse this author
Imai, Shungo Browse this author →KAKEN DB
Kashiwagi, Hitoshi Browse this author
Sato, Yuki Browse this author
Sugawara, Mitsuru Browse this author
Takekuma, Yoh Browse this author →KAKEN DB
Keywords: Linezolid
Nausea and vomiting
Adverse drug effects
Issue Date: 1-Feb-2022
Publisher: Springer
Journal Title: European Journal of Clinical Pharmacology
Volume: 78
Issue: 2
Start Page: 279
End Page: 286
Publisher DOI: 10.1007/s00228-021-03221-x
Abstract: Purpose Some clinical studies have reported the occurrence of nausea and vomiting with linezolid (LZD) administration. However, no studies have evaluated nausea and vomiting as primary endpoints. In a previous study, we noted a possible relationship between LZD and vomiting, but risk factors were not identified. Therefore, the aim of the present study was to identify them. Methods Patients who received LZD 600 mg twice daily at Hokkaido University Hospital from September 2008 to April 2019 were enrolled in this retrospective observational study. Patient characteristics, concomitant medications, laboratory data, and the occurrence of vomiting were obtained from electronic medical records. Logistic regression analysis was performed to identify risk factors for vomiting, including age, sex, body weight, concomitant medications, and surgeries. Results A total of 496 patients were included in this study, of which 90 experienced vomiting. By multivariate logistic regression analysis, female sex (adjusted odds ratio [aOR], 2.69; 95% confidence interval [CI], 1.62-4.47), >= 10 days of LZD administration (aOR, 2.57; CI, 1.46-4.50), and hyponatraemia (aOR, 2.96; CI, 1.72-5.10) were identified as independent risk factors for vomiting; administration of serotonergic agents (aOR, 0.23; CI, 0.07-0.82) was negatively associated. Conclusions This study is the first to successfully identify risk factors for LZD-induced vomiting. Careful monitoring of patients with these risk factors may lead to safer and sustainable LZD administration.
Rights: The final publication is available at Springer via
Type: article (author version)
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 武隈 洋

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University